Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL
(MedPage Today) -- In the first randomized comparison of targeted agents for acute lymphoblastic leukemia (ALL), ponatinib (Iclusig) prevailed over imatinib for untreated Philadelphia chromosome-positive (Ph+) cases.
More than twice as many patients...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Gleevec | Hematology | Leukemia